Evidence-based personas put behaviour at the centre of customer intelligence

Tern plc

Personas are useful when they help a business understand how people think, decide and act. They are less useful when they simply create a polished version of what a customer might say. That distinction is becoming more important as artificial intelligence makes it easier to generate convincing customer profiles at speed.

Synthetic personas can appear highly realistic. They can answer questions, react to messages and simulate preferences. This makes them useful for quick testing, creative development and early exploration. The risk is that they may reflect what a model assumes a person would say rather than what real people are likely to do.

Evidence-based personas take a different approach. They are built from real-life data and behavioural signals, with synthetic data used to improve and optimise the model. This matters because commercial decisions need more than plausible language. They need insight into behaviour, timing, barriers, motivations and likely action.

Synthetic personas focus mainly on what people say. Evidence-based personas focus on what people do. That makes them more relevant when decisions carry greater risk, when audiences are complex, or when timing matters. In sectors such as healthcare and life sciences, where customer behaviour can be shaped by regulation, professional context and patient need, a stronger evidence base can improve the quality of decision-making.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls in protecting physical equipment.

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

Search